Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

News

WCLC 2022: Noninferiority Trial of Lobar or Sublobar Resection for Peripheral NSCLC

News

WCLC 2022: Interim Analysis of Overall Survival With Atezolizumab in Resected NSCLC From IMpower010

News

T-DXd Receives Accelerated Approval From the FDA for Treatment of HER2-Mutant NSCLC

News

Capmatinib Granted Regular Approval by the FDA in Treatment of Metastatic NSCLC

Medical Literature

Research Shows Anticancer Potential of Natural Compound Found in Barberry Plants

News

WCLC 2022: Biomarker-Directed Study of Treatment Options in NSCLC After Immunotherapy

News

COVID-19 Vaccination in Immune Checkpoint Inhibitor–Treated Patients With Lung Cancer in Japan

Stephanie T. Schmidt, PhD, on Neoadjuvant Chemotherapy and Immune-Based Treatments in NSCLC

Nasser K. Altorki, MD: Expert Perspective on the IMpower010 Study of Atezolizumab for NSCLC

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

(UPDATE) Pembrolizumab (Keytruda) in NSCLC

(UPDATE) Nivolumab (Opdivo) in NSCLC

(UPDATE) Afatinib (Gilotrif)

Sotorasib

View More

More

News

Newly Identified HER2 Mutations in Non–Small Cell Lung Cancer Focus on Exons 18 and 19

Baseline Body Mass Index and Outcomes in Chemoimmunotherapy-Treated Lung Cancer

Does Long-Term Exposure to Wildfires Increase the Risk for Lung Cancer?

ASCO 2022: Expanded Cohort Update on Larotrectinib for NTRK Fusion–Positive Lung Cancer

WCLC 2022: Biomarker-Directed Study of Treatment Options in NSCLC After Immunotherapy

ASCO 2022: Second-Line Pembrolizumab Plus Ramucirumab in Advanced NSCLC

Does Esophageal-Sparing Radiotherapy Reduce the Risk of Esophagitis in Advanced NSCLC?

Do Patients at High Risk for Lung Cancer Experience Delays in Follow-up Screening?

View More

Advertisement

Published

Medical Literature

Effective Combination Therapy for COVID-19 Featured in a Patient With Lung Cancer

Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel in Advanced Lung Cancer

Can a Deep Learning Algorithm Predict the Risk of Pulmonary Nodules Becoming Cancerous?

CodeBreaK100: Sotorasib for KRAS-Mutated Lung Cancer

View More

Ongoing

CE Activities

Tailoring Targeted Therapy: New Directions for Managing Patients Across the Spectrum of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer: Management of Patients With Resectable Disease

KRAS Mutations in NSCLC: Who, How, and When to Test

Meet The Professor: Current and Future Role of Immunotherapy in the Management of Lung Cancer — Part 1 of a 4-Part Series

View More

Available

Clinical Trials

The University of Texas MD Anderson Cancer Center, NORTHSTAR Trial

Fox Chase Cancer Center

City of Hope Comprehensive Cancer Center

A Randomized Phase II Trial of Adjuvant Pembrolizumab for Stage I Non-Small Cell Lung Cancer with Primary Tumors Between 1-4 cm

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.